Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool October 26, 2007 Alyce Lomax	Skechers Regains Its Footing Things aren't quite as bad for the footwear company as some investors thought.
The Motley Fool November 26, 2010 Brian Orelli	Get It Together, Johnson & Johnson Another day, another recall.
The Motley Fool February 14, 2008 Alyce Lomax	Getting a Kick Out of Skechers Investors liked what they heard from the shoe company in their fourth-quarter posting.
The Motley Fool May 26, 2010 Brian Orelli	Is Johnson & Johnson a Buy? Let's see what it says to Congress first on safety issues.
Entrepreneur September 2004 Melissa Campanelli	Double Play Could sending a paper catalog to customers boost your e-commerce business?
The Motley Fool October 28, 2004 Dave Marino-Nachison	Skechers Misses a Step Profits took a higher than usual tax hit, hurting the shoe company's shares.
The Motley Fool June 4, 2010 Brian Orelli	Out With Drugs, in With Medical Devices Johnson & Johnson's movement in medical devices and diagnostics is headed in the right direction, but whether Johnson & Johnson is a buy depends a lot on how it handles its current drug problem. Unfortunately investors can't have one without the other.
The Motley Fool July 9, 2010 Brian Orelli	Hey, Johnson & Johnson: Eight Is Enough If Johnson & Johnson can't overcome the negative image from recalls quickly, consumers will head to competing brand-name drugs or just grab generic versions of Johnson & Johnson's products.
The Motley Fool February 6, 2009 Alyce Lomax	Skechers Gets Trampled Like consumers, investors should think twice about buying footwear.
The Motley Fool February 28, 2011 Brian Orelli	Johnson & Johnson Parties Like It's 1982 The big pharma announced that it was recalling 667,632 packages of Sudafed tablets because the instructions contained a typo.
The Motley Fool February 22, 2008 Alyce Lomax	Stock of the Week: Skechers Take a look at Skechers, which offers a wide array of casual shoes, boots, and athletic footwear. Like some of its peers, its stock has taken quite a beating, but perhaps this shoe retailer has been scuffed up just a little too much.
The Motley Fool July 14, 2008 Brian Orelli	Foolish Forecast: J&J Trudges Along In advance of earnings analysts wonder if Johnson & Johnson is a recovery story waiting to happen, or still stuck in a rut?
CRM March 2010 Christopher Musico	Email Management You've Got Mail: Despite fits and starts, many still believe email management solutions can deliver on their promise.
The Motley Fool June 25, 2010 Brian Orelli	The Joys of Being Large and Diversified Johnson & Johnson's plant closure is a rounding error.
The Motley Fool October 19, 2011 Brian Orelli	Not the Best Quarter, but... There's little reason to worry about Johnson & Johnson.
The Motley Fool June 28, 2011 Eric Bleeker	Johnson & Johnson Is Looking Abroad for Growth Where's Johnson & Johnson generating its sales?
The Motley Fool July 19, 2011 Brian Orelli	J&J: Better, but Not Best A decent-looking quarter, but a turnaround could still take awhile.
The Motley Fool July 12, 2011 Todd Wenning	What Does Johnson & Johnson Do With Its Free Cash? Johnson & Johnson appears to be making fair use of its free cash flow, and its well-covered dividend may be attractive to income-focused investors.
The Motley Fool January 18, 2012	What Johnson & Johnson Does With Its Cash Over the last five years, Johnson & Johnson shares returned 14%, which drops to -3% without dividends -- not a bad boost to top off otherwise lowly share performance.
The Motley Fool August 14, 2008 Alyce Lomax	Skechers + Heelys = Sketchy? Skechers has now publicly disclosed that it would like to acquire the wheeled wonder Heelys. Is it the right move?
The Motley Fool May 6, 2010 Brian Orelli	Johnson & Johnson, What Have You Done? We're not sure, but Congress wants to find out. The House Committee on Oversight and Government Reform launched an investigation yesterday into the recall JNJ announced last week.
The Motley Fool August 24, 2010 Brian Orelli	One Day, the J&J Recalls Will End Just not today. Johnson & Johnson's consumer health segment gets more than half of its sales from outside the U.S., so tainting its image outside the U.S. could be costly as well.
The Motley Fool June 15, 2011 Brian Orelli	Johnson & Johnson Is a Quitter The diversified health-care giant has decided to exit the drug-eluting stent market.
The Motley Fool July 31, 2007 Nathan Parmelee	Break Out the Band-Aids at J&J Johnson & Johnson is making some deep cuts to change its cost structure. Shareholders haven't had much to cheer about lately here, but the potential benefits from this move could help cure some of the current softness in the business.
The Motley Fool July 20, 2010 Brian Orelli	Is J&J a Bad News Buy? Another quarter in 2010, another lowered earnings guidance for Johnson & Johnson. At least the year is half over for the health-care giant.
The Motley Fool August 24, 2009 Brian Orelli	J&J Would Rather Not Say Drug delayed, reason unknown. Should shareholders be worried? It's hard to tell.
The Motley Fool August 27, 2010 Brian Orelli	A Recall a Week, That's All We Ask For Johnson & Johnson, apparently that's too much.
The Motley Fool August 14, 2007 Brian Orelli	A No-Win Situation Johnson & Johnson is suing the beloved American Red Cross for trademark infringement. Johnson & Johnson just needs to walk a fine line between having its brand eroded by the Red Cross and having its brand eroded by a public relations nightmare.
The Motley Fool January 26, 2011 Brian Orelli	J&J Will Recover -- Someday Consumer health care might be the smallest of Johnson & Johnson's three divisions, but the 15% drop in revenue still hurts. A lot.
The Motley Fool October 6, 2009 Jennifer Schonberger	This Is How We Should Fix the Financial System Economist Simon Johnson says a decision about regulating derivatives was the defining event.
The Motley Fool May 28, 2010 Brian Orelli	How Much Is This Going to Cost J&J? Investors need an answer from Johnson & Johnson about low-quality drugs that were recalled. Is the problem systemic, and if so, how much will it cost the company to fix the problem?
The Motley Fool November 21, 2008 Brian Orelli	Manufacturing Pain Johnson & Johnson has plenty of it.
Inc. April 2004 Alison Stein Wellner	Case Study Colin Johnson had a bold plan to transform his consulting firm. But when things went awry, sticking to his guns meant risking everything.
The Motley Fool December 1, 2010 Brian Orelli	We're Still Buying. Probably. Despite manufacturing problems, Johnson &Johnson continues with its purchase of Crucell.
The Motley Fool September 30, 2009 Brian Orelli	Boston Scientific Pays Up And Johnson & Johnson reaps the rewards.
Financial Planning June 1, 2010 Jim Grote	Under One Roof Timothy E. Johnson has grown his business by listening to his clients' needs-and creating an in-house solution for each of them.
The Motley Fool January 26, 2010 Brian Orelli	Is the Best of Johnson & Johnson Behind It? Johnson & Johnson announces that its sales fell for the first time in 76 years.
The Motley Fool August 19, 2010 Brian Orelli	Buffett Is Buying J&J. Should You? It depends on your time horizon.
The Motley Fool December 8, 2004 Dave Marino-Nachison	J&J Guided to Guidant? Medical device investors felt their hearts skip as executives told The New York Times the two companies may be set to merge.
The Motley Fool January 23, 2008 Brian Orelli	A Dose of Stability From J&J Top-line growth looked great at Johnson & Johnson -- more than 16% year over year -- but when you dove a little further into the earnings, growth wasn't quite that stellar.
CRM February 2011 Koa Beck	Information Overload Unilever's unsightly knowledge base was costing the company money, customer satisfaction, and time -- until it turned to Astute Solutions
The Motley Fool December 31, 2009 Brian Orelli	The FDA (Still) Hates Antibiotic Makers Johnson & Johnson and Basilea are the agency's latest victims.
The Motley Fool May 12, 2010 Nick Kapur	J&J: A Winner on Both Sides of the Ball (Fool TV) If you're looking to build a dynasty in your portfolio, you'd be hard-pressed to find a better-balanced outfit than veteran Johnson & Johnson. The consumer products giant is discussed in this video.
The Motley Fool October 12, 2004 Alyce Lomax	Take It Away, J&J Should investors sweat a coming slowdown in growth for pharmaceutical and consumer products giant Johnson & Johnson?
The Motley Fool February 22, 2010 Brian Orelli	So Long, See You in Arbitration After another rejection, Johnson & Johnson and Basilea call it quits.
The Motley Fool September 14, 2009 Brian Orelli	The Clock Is Ticking for Elan Elan is getting closer to the Sept. 26 deadline to fix its contract with Johnson & Johnson. If it doesn't, Biogen Idec has the right to take full control of Elan's and Biogen's multiple-sclerosis drug, Tysabri.
The Motley Fool September 27, 2010 Brian Orelli	This Recall Is Different -- In a Good Way Johnson & Johnson strikes again, but it's not so bad this time.
The Motley Fool October 19, 2010 Brian Orelli	Watch a 40% Decline Disappear The greatest thing going for Johnson & Johnson is its diversity in product offerings.
The Motley Fool October 23, 2009 Rob Plaza	Skechers Kicks It Up a Notch But it better not kick off its shoes and relax.
CIO May 1, 2003 Meridith Levinson	ASPs: The Next Chapter Application service providers are increasingly viewed as a viable option in the CRM space, particularly for small and midsize companies.